Skip to main content
MedoxyMedoxyHealthcare Pvt Ltd

Documentation & Compliance

Evaluate evidence in the context of the product and transaction.

This page describes Medoxy's inquiry process; it does not claim that Medoxy, every vendor, or every catalogue entry holds a particular certification or authorization.

Evidence by scope

A certificate or record should be matched to the named legal entity, site, product, activity, market, and validity period.

Product identity

Current labels, pack details, composition records, and storage information should be checked for the exact configuration under review.

Market requirements

Licensing, classification, labelling, and distribution obligations depend on the product, role, jurisdiction, and current law.

Qualified requests

Medoxy can confirm which product-specific records are applicable and available in response to a defined business inquiry.

Authoritative references

The World Health Organization publishes guidance on good storage and distribution practices, while India's Central Drugs Standard Control Organization publishes applicable Acts, Rules, and notices. Requirements should be verified against current official material and qualified advice for the specific transaction.

WHO storage and distribution guidanceCDSCO Acts and Rules

Medoxy Healthcare Pvt Ltd is a B2B pharmaceutical trading company based in Gurgaon, Haryana, India, focused on a gastroenterology product catalogue for distributors, stockists, hospitals, institutions, and other qualified healthcare businesses. The product catalogue lists brand names, compositions, dosage forms, and pack sizes across categories such as proton pump inhibitor combinations, antispasmodics, ursodeoxycholic acid, rifaximin, probiotics, antacid and alginate suspensions, and nutritional supplements.

Catalogue entries include Benzispa SR (Mebeverine Hydrochloride Sustained Release), Benzispa Plus (Mebeverine + Chlordiazepoxide), Esomizole-D (Esomeprazole (EC) + Domperidone (SR)), Ursofiz 300 (Ursodeoxycholic Acid IP 300 mg), Ushield (Sucralfate + Oxetacaine), Esomizole-40 (Esomeprazole 40 mg with Sodium Bicarbonate as buffer), Edoflora (Lyophilized Saccharomyces boulardii 250 mg), Menzovit (Multivitamin, Multimineral, Antioxidants, Iron & Zinc), Finozyme Q10 (Coenzyme Q10 + L-Arginine + Omega-3 fatty acid + Selenium + Lycopene), Esomizole-IT (Esomeprazole (EC) + Itopride (SR)), Ursofiz 450 (Ursodeoxycholic Acid Sustained Release), U Raft (Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate), Rifadoxy 400 (Rifaximin IP 400 mg) and Rifadoxy 550 (Rifaximin IP 550 mg). Names, compositions, images, packaging, and availability may change or differ by market. Verify the exact product and current documents before any regulatory, procurement, or commercial decision.

1. Website content is provided for business and informational purposes only and is not a substitute for professional medical advice, diagnosis, treatment, or approved prescribing information. Patients should consult a qualified healthcare professional.

2. This website does not sell medicines online, display pricing, or accept consumer orders. A listing or inquiry response is not an offer of supply or a guarantee of availability. Terms apply.

3. References to quality, compliance, or external guidelines do not by themselves establish a particular licence, approval, or certification. Evidence applicable to a defined transaction can be requested through the trade inquiry form. See Trade & Quality and Compliance for more information.

Articles on the Healthcare Insights blog follow our content policy. Personal data submitted through inquiry forms is handled as described in the privacy policy.